Andreas Weihofen

List of Publications by Year
in descending order

23 papers	3,341 citations	394286 19 h-index	642610 23 g-index
25 all docs	25 docs citations	25 times ranked	5794 citing authors

#	Article	IF	Citations
1	Neurodegeneration and neuroinflammation are linked, but independent of alphaâ€synuclein inclusions, in a seeding/spreading mouse model of Parkinson's disease. Glia, 2022, 70, 935-960.	2.5	30
2	Discovery of small-molecule positive allosteric modulators of Parkin E3 ligase. IScience, 2022, 25, 103650.	1.9	11
3	Lysophosphatidylcholine acyltransferase 1 promotes pathology and toxicity in two distinct cell-based alpha-synuclein models. Neuroscience Letters, 2022, 772, 136491.	1.0	3
4	A Stearoylâ€"Coenzyme A Desaturase Inhibitor Prevents Multiple Parkinson Disease Phenotypes in <scp>Î±</scp>â€Synuclein Mice. Annals of Neurology, 2021, 89, 74-90.	2.8	40
5	Î±-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinsonâ€™s disease. JCI Insight, 2021, 6, .	2.3	60
6	SCD Inhibition Protects from Î±-Synuclein-Induced Neurotoxicity But Is Toxic to Early Neuron Cultures. ENeuro, 2021, 8, ENEURO.0166-21.2021.	0.9	8
7	Wild-type GBA1 increases the Î±-synuclein tetramerâ€"monomer ratio, reduces lipid-rich aggregates, and attenuates motor and cognitive deficits in mice. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	21
8	The Parkinsonâ€™s disease-associated gene ITPKB protects against Î±-synuclein aggregation by regulating ER-to-mitochondria calcium release. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	35
9	Randomized phase I clinical trial of antiâ€"Î±â€synuclein antibody BIIB054. Movement Disorders, 2019, 34, 1154-1163.	2.2	128
10	Development of an aggregate-selective, human-derived Î±-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models. Neurobiology of Disease, 2019, 124, 276-288.	2.1	125
11	LRRK2 Antisense Oligonucleotides Ameliorate Î±-Synuclein Inclusion Formation in a Parkinsonâ€™s Disease Mouse Model. Molecular Therapy - Nucleic Acids, 2017, 8, 508-519.	2.3	167
12	The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. Journal of Neurochemistry, 2011, 117, 856-867.	2.1	313
13	Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. Human Molecular Genetics, 2009, 18, 4317-4328.	1.4	77
14	Pink1 Forms a Multiprotein Complex with Miro and Milton, Linking Pink1 Function to Mitochondrial Trafficking. Biochemistry, 2009, 48, 2045-2052.	1.2	277
15	Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1. Human Molecular Genetics, 2008, 17, 602-616.	1.4	138
16	Dopamine covalently modifies and functionally inactivates parkin. Nature Medicine, 2005, 11, 1214-1221.	15.2	658
17	Consensus Analysis of Signal Peptide Peptidase and Homologous Human Aspartic Proteases Reveals Opposite Topology of Catalytic Domains Compared with Presenilins. Journal of Biological Chemistry, 2004, 279, 50790-50798.	1.6	90
18	Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides. Trends in Cell Biology, 2003, 13, 71-78.	3.6	197

#	Article	IF	Citations
19	Post-transcriptional Regulation of the Streptomyces coelicolor Stress Responsive Sigma Factor, SigH, Involves Translational Control, Proteolytic Processing, and an Anti-sigma Factor Homolog. Journal of Molecular Biology, 2003, 325, 637-649.	2.0	42
20	Targeting Presenilin-type Aspartic Protease Signal Peptide Peptidase with Î³-Secretase Inhibitors. Journal of Biological Chemistry, 2003, 278, 16528-16533.	1.6	114
21	Identification of Signal Peptide Peptidase, a Presenilin-Type Aspartic Protease. Science, 2002, 296, 2215-2218.	6.0	521
22	Intramembrane Proteolysis of Signal Peptides: An Essential Step in the Generation of HLA-E Epitopes. Journal of Immunology, 2001, 167, 6441-6446.	0.4	167
23	Release of Signal Peptide Fragments into the Cytosol Requires Cleavage in the Transmembrane Region by a Protease Activity That Is Specifically Blocked by a Novel Cysteine Protease Inhibitor. Journal of Biological Chemistry, 2000, 275, 30951-30956.	1.6	111